For the first time in the US, a 28-year old patient with Duchenne’s muscular dystrophy (DMD), Ryan Benton, received mesenchymal stem cell treatment based on umbilical cord tissue. The US FDA approved the treatment application for a single patient for compassionate use.
Duchenne muscular dystrophy is a muscle degenerative disease that affects mainly boys. It is caused by a gene mutation that results in inability of the body muscles to produce the protein dystrophin. As a result, DMD patients experience progressive muscle weakness and loss of muscle function. By the age of 25, the majority of DMD patients die mainly from lung disorders.
The patient has received the first intramuscular stem cell injections for the four consecutive days. The treatment will be repeated every 6 months for a total of 3 years.
Ryan already underwent stem cell treatment derived from umbilical cord mesenchymal cells before in Panama. Promising results from these treatments encouraged his doctor to look for a way to treat the patient in the US.
||Rezultat tretmana fetalnim matičnim ćelijama zavisi od: težine bolesti, starosne dobi pacijenta, doslednosti i privrženosti medikaciji i režimu. Rezultati tretmana, prezentovani na ovom sajtu, su individualni za svaki klinički slučaj.|